Effect of Tezepelumab on Lung Function in Patients With Severe, Uncontrolled Asthma in the Phase 3 NAVIGATOR Study
Open Access
- 19 September 2023
- journal article
- research article
- Published by Springer Nature in Advances in Therapy
- Vol. 40 (11) , 4957-4971
Abstract
Introduction Severe asthma is associated with airway inflammation and airway obstruction. In the phase 3 NAVIGATOR study, tezepelumab treatment significantly improved pre-bronchodilator forced expiratory volume in 1 s (FEV1) compared with placebo in patients with severe, uncontrolled asthma. This analysis assessed the effect of tezepelumab versus placebo on additional lung function parameters in patients from NAVIGATOR. Methods NAVIGATOR was a multicenter, randomized, double-blind, placebo-controlled study. Patients (12–80 years old) receiving medium- or high-dose inhaled corticosteroids and at least one additional controller medication, with or without oral corticosteroids, were randomized 1:1 to tezepelumab 210 mg or placebo subcutaneously every 4 weeks for 52 weeks. Changes from baseline to week 52 in pre-bronchodilator FEV1, post-bronchodilator FEV1, forced vital capacity (FVC), pre-bronchodilator FEV1/FVC ratio, pre-bronchodilator forced expiratory flow between 25 and 75% of vital capacity (FEF25–75), and morning and evening peak expiratory flow (PEF) were assessed. Results Tezepelumab treatment improved all evaluated lung function parameters over 52 weeks compared with placebo [least-squares mean difference (95% confidence interval): pre-bronchodilator FEV1, 0.13 (0.08, 0.18) L; post-bronchodilator FEV1, 0.12 (0.07, 0.16) L; FVC, 0.13 (0.07, 0.19) L; FEV1/FVC ratio, 2.06% (1.22%, 2.90%); FEF25–75, 0.13 (0.07, 0.19) L/s; morning PEF, 16.6 (8.1, 25.1) L/min; and evening PEF, 14.9 (6.3, 23.4) L/min]. Improvements were observed as early as weeks 1–2 and were maintained over 52 weeks. Greater improvements in lung function compared with placebo were observed in patients with a disease duration of less than 20 years, those with baseline post-bronchodilator FEV1 reversibility of at least 20%, and in patients with a baseline post-bronchodilator FEV1/FVC ratio of less than 0.7. Conclusion These findings further support the benefits of tezepelumab treatment in improving airflow limitation in patients with severe, uncontrolled asthma. Clinical Trial Registration NAVIGATOR (NCT03347279).Keywords
Funding Information
- AstraZeneca
- Amgen
This publication has 35 references indexed in Scilit:
- Omalizumab for asthma in adults and childrenCochrane Database of Systematic Reviews, 2014
- Lung function decline in asthmaEuropean Respiratory Journal, 2007
- Severe exacerbations predict excess lung function decline in asthmaEuropean Respiratory Journal, 2007
- Airway remodeling contributes to the progressive loss of lung function in asthma: An overviewJournal of Allergy and Clinical Immunology, 2005
- Standardisation of spirometryEuropean Respiratory Journal, 2005
- Benefits of omalizumab as add‐on therapy in patients with severe persistent asthma who are inadequately controlled despite best available therapy (GINA 2002 step 4 treatment): INNOVATEAllergy, 2004
- Risk factors associated with the presence of irreversible airflow limitation and reduced transfer coefficient in patients with asthma after 26 years of follow upThorax, 2003
- Duration of Asthma and Physiologic Outcomes in Elderly NonsmokersAmerican Journal of Respiratory and Critical Care Medicine, 2000
- What are minimal important changes for asthma measures in a clinical trial?European Respiratory Journal, 1999
- Asthma and irreversible airflow obstruction.Thorax, 1984